drugset
drugset / Trial / NCT04311671

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

NCT04311671 ↗

Phase 3 Completed 12979 enrolled Medicines Development for Global Health
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.

Timeline

Start
2021-05-03
Primary completion
2024-09-27
Completion
2024-09-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ivermectin Small molecule 150 ug/kg Oral
Subject Moxidectin Other / unclassified 8 mg Oral
Background Albendazole Small molecule 400 mg Oral

Indications

onchocerciasis